ReNAgade Therapeutics Management, Inc.
ReNAgade is a part of Orna Therapeutics, focusing on circular RNA therapies. It is strategically acquired by Orna Therapeutics to strengthen leadership in circular RNA therapies.
Industries
Nr. of Employees
medium (51-250)
ReNAgade Therapeutics Management, Inc.
Cambridge, Massachusetts, United States, North America
Patents
Products
RNA Delivery Systems
A portfolio of systems designed for delivering RNA to previously inaccessible cells, expanding the range of diseases that can be addressed.
RNA Coding Platform
A platform developed in joint venture with Orna Therapeutics for reprogramming cells with superior expression capabilities.
Gene Editing Technology
Proprietary technology enabling the permanent correction of defective genes to facilitate curative therapies.
Gene Therapy 2.0 Platform
An all-RNA system for enabling exon or large gene insertions, representing an advancement in gene therapy.
RNA Delivery Systems
A portfolio of systems designed for delivering RNA to previously inaccessible cells, expanding the range of diseases that can be addressed.
RNA Coding Platform
A platform developed in joint venture with Orna Therapeutics for reprogramming cells with superior expression capabilities.
Gene Editing Technology
Proprietary technology enabling the permanent correction of defective genes to facilitate curative therapies.
Gene Therapy 2.0 Platform
An all-RNA system for enabling exon or large gene insertions, representing an advancement in gene therapy.
Expertise Areas
- Circular RNA therapeutics
- RNA therapeutic development
Key Technologies
- Circular RNA (circRNA) platforms
- RNA therapeutics
News & Updates
This article discusses the strategic acquisition of ReNAgade Therapeutics by Orna Therapeutics, aimed at solidifying leadership in circular RNA therapies.
This article discusses the strategic acquisition of ReNAgade Therapeutics by Orna Therapeutics, aimed at solidifying leadership in circular RNA therapies.